European Commission 10 April 2026, Proposal for a COUNCIL DECISION on the position to be taken on behalf of the European Union within the CETA Joint Committee established under the Comprehensive Economic and Trade Agreement (CETA) between Canada, of the one part, and the European Union and its Member States, of the other part, as regards the adoption of a decision concerning the inclusion of active pharmaceutical ingredients as the medicinal products or drugs listed in paragraph 2 of the Annex 1 to the Protocol on the mutual recognition of the compliance and enforcement programme regarding good manufacturing practices for pharmaceutical products

Also known as